secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001601485-23-000077
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics Q3 net loss $10.7M; ELI-002 RFS 16.3 months, Phase 2 planned early 2024
--------------------------------------------------------------------------------

- Net loss of $10.7M ($1.27/sh) vs $7.2M loss ($22.67/sh) in Q3 2022; cash $14.1M vs $6.2M year-end 2022.
- ELI-002 2P showed median relapse-free survival of 16.3 months; T-cell response correlated with 86% risk reduction (HR 0.14, p=0.013).
- ELI-002 7P Phase 2 monotherapy trial in adjuvant PDAC to start early 2024; interim analysis expected Q1 2025.
- R&D expense $7.3M (+58% YoY) and G&A $3.5M (+198% YoY) driven by public company costs and trial expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000077/0001601485-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000077/angn-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer